CNTB — Connect Biopharma Holdings Income Statement
0.000.00%
- $87.41m
- -$30.78m
- 22
- 36
- 79
- 43
Annual income statement for Connect Biopharma Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 16 | 28.7 | 98.1 | 119 | 62.1 |
Operating Profit | -16 | -28.7 | -98.1 | -119 | -62.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -24.4 | -113 | -202 | -118 | -59.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -24.4 | -113 | -202 | -118 | -59.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -24.4 | -113 | -202 | -118 | -59.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -24.4 | -113 | -202 | -118 | -59.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.437 | -2.02 | -3.88 | -2.09 | -1.08 |